Breast Cancer | Disease Landscape & Forecast | G7 | 2023
The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios) are entrenched in the treatment of HR-positive / HER2-negative disease, a trend that will continue through 2032. Current treatment options for HER2-positive breast cancer have expanded, owing to the launch of novel HER2-targeting agents (Daiichi Sankyo / AstraZeneca’s Enhertu, Seagen / Pfizer’s Tukysa, and MacroGenics’ Margenza), sales of which will offset the entry of generics and biosimilars. In triple-negative breast cancer, the approvals of PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza, Pfizer’s Talzenna), immune checkpoint inhibitors (Merck & Co.’s Keytruda), and TROP2-targeted agents (Gilead’s Trodelvy) are diversifying therapy options for patients. Enhertu’s approval in 2022 for HER2-low disease, a new subset of breast cancer, will further reshape the treatment landscape.
QUESTIONS ANSWERED
- What is the size of clinically and commercially relevant drug-treatable breast cancer populations, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals, such as Trodelvy, Keytruda, Piqray, Enhertu, and Orserdu, on the various subpopulations of breast cancer?
- Which are the most promising agents in the pipeline, and how will they shape the future of the breast cancer therapy market?
- Which key drivers and constraints will affect the breast cancer therapy market over the forecast period?
CONTENT HIGHLIGHTS
- Geographies: United States, EU5, Japan.
- Primary research: 18 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other Clarivate research.
- Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy.
- Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2032, segmented by brands / biosimilars / generics and market-relevant drug-treatable populations.
- Emerging therapies: Phase 3/PR: 20 drugs; coverage of select Phase 1 and 2 products.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
